ArticleFuture oncology (London, England)2026

OPERA-01: a phase III study of palazestrant for ER+, HER2- advanced breast cancer after CDK4/6 inhibitor therapy.

Barbara Pistilli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.